Overview

Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE

Status:
Terminated
Trial end date:
2020-05-02
Target enrollment:
Participant gender:
Summary
In an open-label parallel groups blinded-endpoint randomized clinical trial, the investigators aim to assess the safety and efficacy of conventional catheter-directed thrombolysis (CDT) vs anticoagulation monotherapy on outcomes of patients with acute intermediate-high risk pulmonary embolism. The investigators hypothesize that CDT will have a superior efficacy and safety compared with anticoagulation-only therapy regarding the proportion of patients with a right ventricle to left ventricle (RV/LV) ratio > 0.9 at a 3-month follow-up by an imaging core laboratory, major bleeding, severe thrombocytopenia, or vascular access complication.
Phase:
Phase 3
Details
Lead Sponsor:
Rajaie Cardiovascular Medical and Research Center
Treatments:
Dalteparin
Enoxaparin
Heparin
Heparin, Low-Molecular-Weight
Plasminogen
Tinzaparin
Tissue Plasminogen Activator